Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen

Update Il y a 4 ans
Reference: EUCTR2004-001457-28

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the overall response rate (complete plus partial response) of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.


Inclusion criteria

  • Advanced metastatic ovarian cancer